🧠 Immune Memory Kineticsimmunology
1st exposure→
naive lymphocyte activation→
effector + memory cells→
2nd exposure→
fast, large recall response
- Primary response
- Lag of ~5–10 days before detectable antibody
- Small peak magnitude
- IgM dominates early, IgG appears later
- Low, variable antibody affinity
- Triggered by any immunogen (protein or non-protein)
- Secondary (recall) response
- Lag shortened to ~1–3 days
- Much larger peak magnitude
- Rapid class switching toward IgG/IgA/IgE
- High affinity — driven by germinal-center affinity maturation
- Requires a protein antigen to engage T-cell help
Why it's fastPre-expanded memory clones already exist body-wide, so the response starts from a much larger founder population than the naive repertoire did.
🛡️ Active vs. Passive Immunityimmunology
| Route | Natural | Artificial |
|---|---|---|
| Active (host makes its own response + memory) | Surviving a natural infection | Vaccination with a live, killed, or component antigen |
| Passive (pre-formed antibody transferred in) | Transplacental IgG; IgA in colostrum | Antitoxin, antivenin, pooled immunoglobulin, monoclonal antibody |
- Active immunization → slow onset, long-lasting (memory formed)
- Passive immunization → immediate but temporary protection (no memory formed)
- Passive protection is chosen when there isn't time to wait for active immunity — post-exposure prophylaxis, toxin neutralization
⚠️ Risks of Passive Antibody Therapyclinical
- Non-human (animal-derived) antibody
- Recognized as foreign → can provoke an IgE response → risk of systemic anaphylaxis
- Can also form IgG/IgM anti-isotype complexes → complement activation → type III hypersensitivity (serum sickness pattern)
- Human-derived pooled immunoglobulin
- Can still trigger IgE formation in a recipient with selective IgA deficiency, since their immune system has never "seen" IgA before
- These patients should receive IgA-depleted product
- Even matched-species antibody can provoke a response against minor genetic variants of immunoglobulin (allotypes)
Exam trapSelective IgA deficiency (roughly 1 in 700 people) is the classic setup for an anaphylactoid reaction to immunoglobulin products.
🦠 Live Vaccinesplatform
- Attenuated (weakened) organisms
- Still replicate transiently in the host → mimics real infection
- Drives both humoral and cell-mediated immunity → typically durable, lifelong protection
- Usually one dose is protective; a second dose is given mainly to catch non-responders
- Contraindicated in immunocompromised hosts — even a weakened organism can cause disease, and there is a small risk of reversion to a virulent strain
- Live attenuated examples in routine use: MMR, varicella/zoster, rotavirus, intranasal influenza
- Live attenuated used only in special situations: oral polio (Sabin), smallpox, yellow fever
- Non-attenuated live vaccine (rare category)
- Used in a military setting against certain adenovirus serotypes
- Given as an enteric-coated capsule so the virus replicates in the gut, not the respiratory tract
- Produces a silent gut infection that seeds mucosal IgA memory, which then protects the respiratory mucosa against the same virus
💉 Killed & Toxoid Vaccinesplatform
- Killed / inactivated whole-organism vaccines
- Organism can no longer replicate
- Inactivated chemically (heat would destroy the key surface epitopes)
- Mainly drive humoral (antibody) immunity, not cellular
- Need repeat dosing to reach protective levels
- Examples: injected (Salk) polio, rabies, inactivated influenza, hepatitis A
- Toxoid vaccines
- Made from a bacterial exotoxin that has been inactivated
- Prevents the disease caused by the toxin, not colonization/infection itself
- Example: DTaP — diphtheria toxoid + tetanus toxoid + acellular pertussis antigens
- Generally well tolerated with a favorable safety profile
🧬 Polysaccharide, Conjugate & Component Vaccinesplatform
- Pure polysaccharide vaccines
- Built from a bacterium's capsular sugar coat
- Sugars can't be presented on MHC to helper T cells → response is T-independent
- Result: IgM only, weak memory, poor response in children under 2
- Example: 23-valent pneumococcal polysaccharide — reserved for adults >65 or special risk groups (asplenia, COPD)
- Conjugate vaccines — the fix for that problem
- Capsular polysaccharide is chemically linked to a carrier protein (often a toxoid)
- Carrier protein is presentable on MHC-II → recruits T-cell help → class switching, affinity maturation, and true memory
- Produces a proper booster effect on repeat dosing — safe and effective even in infants
- Examples: Hib, 13-valent pneumococcal conjugate, meningococcal conjugate
- Component (subunit) vaccines
- Use one purified immunogenic protein instead of the whole organism
- Often manufactured by recombinant expression in yeast, then purified
- Example: hepatitis B — surface antigen gene expressed in yeast, harvested, purified
- Example: HPV — virus-like particle vaccines; newer formulation covers more oncogenic serotypes than the original
| Platform | T-cell help? | Typical antibody | Works in infants? |
|---|---|---|---|
| Pure polysaccharide | No | IgM only | Poor |
| Conjugate | Yes (via carrier) | IgG, class-switched | Yes |
👶 Immunoglobulins in the Fetus & Neonatedevelopment
- Only IgG crosses the placenta (active transport) → newborn's early IgG is entirely maternal
- Maternal IgG declines over the first several months as infant's own production ramps up
- Because maternal IgG masks early infection, IgM is the only isotype useful for diagnosing a true neonatal infection (it doesn't cross the placenta)
- Infants with an underlying immune deficiency often look well at birth and only become symptomatic once maternal IgG has waned
- Secretory IgA is not transferred in utero — infants depend on colostrum/breast milk for it, and only reach ~20% of adult IgA levels by 12 months
- Live attenuated vaccines are timed to start after ~12 months of age, because residual maternal antibody would neutralize the vaccine strain before it can replicate and immunize
- Exception: high-risk exposure settings may justify earlier dosing, but this usually requires extra booster doses later
⭐ High-Yield Pearlsexam focus
- "Which vaccine is unsafe in an immunocompromised patient?" → live attenuated, every time
- "Which antibody isotype confirms true neonatal infection?" → IgM
- Polysaccharide-only vaccine in a toddler = poor response; conjugate is the fix
- Toxoid ≠ whole killed organism — it neutralizes the toxin, not the infection
- Anaphylaxis to IV immunoglobulin → think selective IgA deficiency
- Secondary response = faster + bigger + higher affinity, because of pre-existing memory clones